Literature DB >> 17883591

The plasma kallikrein-kinin system: its evolution from contact activation.

A H Schmaier1, K R McCrae.   

Abstract

The plasma kallikrein-kinin system consists of the proteins factor XII (FXII), prekallikrein (PK), and high molecular weight kininogen. It was first recognized as a surface-activated coagulation system that is activated when blood or plasma interacts with artificial surfaces. Although surface-activated contact activation occurs in vivo in the case of tissue destruction or a developing thrombus, the physiologic basis for the activation and function of this system has not been delineated. New investigations indicate that there is a proteolytic pathway on cells for PK activation independent of FXII. This pathway for PK with subsequent FXII activation indicates physiologic activities. These activities include blood pressure regulation and modulation of thrombosis risk independently of hemostasis. Furthermore, they include regulation of endothelial cell proliferation, angiogenesis and apoptosis through a cellular-based, outside-in signaling system. The present characterizations of this system, which incorrectly had been thought to initiate coagulation, represent an evolution of understanding in this field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17883591     DOI: 10.1111/j.1538-7836.2007.02770.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  49 in total

Review 1.  Hageman factor, platelets and polyphosphates: early history and recent connection.

Authors:  J Caen; Q Wu
Journal:  J Thromb Haemost       Date:  2010-04-30       Impact factor: 5.824

2.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

Review 3.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 4.  Ferritin for the clinician.

Authors:  Mary Ann Knovich; Jonathan A Storey; Lan G Coffman; Suzy V Torti; Frank M Torti
Journal:  Blood Rev       Date:  2008-10-02       Impact factor: 8.250

Review 5.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

6.  Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits.

Authors:  Dorit Farfara; Emily Feierman; Allison Richards; Alexey S Revenko; Robert A MacLeod; Erin H Norris; Sidney Strickland
Journal:  Glia       Date:  2019-03-18       Impact factor: 7.452

7.  Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction.

Authors:  Yan-Min Long; Xing-Chen Zhao; Allen C Clermont; Qun-Fang Zhou; Qian Liu; Edward P Feener; Bing Yan; Gui-Bin Jiang
Journal:  Nanotoxicology       Date:  2015-09-23       Impact factor: 5.913

8.  Proteomic identification of novel plasma kallikrein substrates in the astrocyte secretome.

Authors:  Jia Liu; Ben-Bo Gao; Edward P Feener
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

9.  Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution.

Authors:  Jennifer N Lilla; Ravi V Joshi; Charles S Craik; Zena Werb
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

10.  Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway.

Authors:  Y Liu; R Pixley; M Fusaro; G Godoy; E Kim; M E Bromberg; R W Colman
Journal:  Oncogene       Date:  2009-06-01       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.